FDA has approved Genentech’s Kadcyla (ado-trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
